68 related articles for article (PubMed ID: 9132630)
1. [Analgesic effects of natural growth hormone release inhibitors and their synthetic analogs. Intraspinal administration].
Beltrutti D; Debernardi F; Pelosi G
Minerva Med; 1997; 88(1-2):39-47. PubMed ID: 9132630
[TBL] [Abstract][Full Text] [Related]
2. The attenuated inhibitory action of octreotide, a somatostatin analogue on GHRH-induced growth hormone response in type I diabetes mellitus.
Krassowski J; Rogala H; Jeske W; Zgliczynski S
Horm Metab Res; 1996 Apr; 28(4):207-8. PubMed ID: 8740200
[No Abstract] [Full Text] [Related]
3. Population pharmacodynamic analysis of octreotide in acromegalic patients.
Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
[TBL] [Abstract][Full Text] [Related]
4. Differential contribution of nitric oxide and cGMP to the stimulatory effects of growth hormone-releasing hormone and low-concentration somatostatin on growth hormone release from somatotrophs.
Luque RM; Rodríguez-Pacheco F; Tena-Sempere M; Gracia-Navarro F; Malagón MM; Castaño JP
J Neuroendocrinol; 2005 Sep; 17(9):577-82. PubMed ID: 16101896
[TBL] [Abstract][Full Text] [Related]
5. Post-exercise abdominal, subcutaneous adipose tissue lipolysis in fasting subjects is inhibited by infusion of the somatostatin analogue octreotide.
Enevoldsen LH; Polak J; Simonsen L; Hammer T; Macdonald I; Crampes F; de Glisezinski I; Stich V; Bülow J
Clin Physiol Funct Imaging; 2007 Sep; 27(5):320-6. PubMed ID: 17697029
[TBL] [Abstract][Full Text] [Related]
6. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels.
Befon S; Mystakidou K; Lyra M; Tubanakis N; Vlahos L
Anticancer Res; 2000; 20(5C):4039-46. PubMed ID: 11268498
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
8. [Sandostatin (octreotide)--drug and neurotransmitter (experimental study)].
Gur'ianov VA; Aliautdin RN; Petrov VE; Kuĭian SM
Anesteziol Reanimatol; 2002; (5):68-70. PubMed ID: 12611305
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.
Rice AS; Farquhar-Smith WP; Nagy I
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):243-56. PubMed ID: 12052040
[TBL] [Abstract][Full Text] [Related]
10. [Local administration of somatostatin in joint diseases in athletes].
Russo S; Mangrella M; Vitagliano S; Russo P; Berrino L
Minerva Med; 1997 Jun; 88(6):265-70. PubMed ID: 9280869
[TBL] [Abstract][Full Text] [Related]
11. [Indications for the use of somatostatin and octreotide in digestive pathology].
Zan S; Roy L; Zanon C; Mobiglia A; Mussa B; Raviola P; Mormile C; Ballario R; Giustetto A
Minerva Gastroenterol Dietol; 1996 Jun; 42(2):107-14. PubMed ID: 8962905
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
13. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases.
Paice JA; Penn RD; Kroin JS
Neurosurgery; 1996 Jan; 38(1):203-7. PubMed ID: 8747973
[TBL] [Abstract][Full Text] [Related]
15. Novel molecular aspects of pituitary adenomas.
Hubina E; Ruscica M; Nanzer AM; Czirják S; Góth MI; Grossman AB; Korbonits M
J Endocrinol Invest; 2005; 28(11 Suppl International):87-92. PubMed ID: 16625855
[TBL] [Abstract][Full Text] [Related]
16. The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.
Beltrutti DP; Moessinger S; Varrassi G
Curr Rev Pain; 2000; 4(1):82-90. PubMed ID: 10998719
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
[TBL] [Abstract][Full Text] [Related]
18. Centrally applied somatostatin inhibits the estrogen-induced luteinizing hormone surge via hypothalamic gonadotropin-releasing hormone cell activation in female rats.
Van Vugt HH; Swarts HJ; Van de Heijning BJ; Van der Beek EM
Biol Reprod; 2004 Sep; 71(3):813-9. PubMed ID: 15140796
[TBL] [Abstract][Full Text] [Related]
19. The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors.
Notas G; Kampa M; Nifli AP; Xidakis K; Papasava D; Thermos K; Kouroumalis E; Castanas E
Eur J Pharmacol; 2007 Jan; 555(1):1-7. PubMed ID: 17113072
[TBL] [Abstract][Full Text] [Related]
20. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
